184 related articles for article (PubMed ID: 16333676)
21. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
Lord R; Nair S; Schache A; Spicer J; Somaihah N; Khoo V; Pandha H
J Urol; 2007 Jun; 177(6):2136-40; discussion 2140. PubMed ID: 17509300
[TBL] [Abstract][Full Text] [Related]
22. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
[TBL] [Abstract][Full Text] [Related]
24. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.
Bocci G; Francia G; Man S; Lawler J; Kerbel RS
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12917-22. PubMed ID: 14561896
[TBL] [Abstract][Full Text] [Related]
25. Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts.
Zhang M; Tao W; Pan S; Sun X; Jiang H
Anticancer Drugs; 2009 Jun; 20(5):355-63. PubMed ID: 19318912
[TBL] [Abstract][Full Text] [Related]
26. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy.
Streit M; Stephen AE; Hawighorst T; Matsuda K; Lange-Asschenfeldt B; Brown LF; Vacanti JP; Detmar M
Cancer Res; 2002 Apr; 62(7):2004-12. PubMed ID: 11929817
[TBL] [Abstract][Full Text] [Related]
27. Molecular basis for the induction of an angiogenesis inhibitor, thrombospondin-1, by 5-fluorouracil.
Zhao HY; Ooyama A; Yamamoto M; Ikeda R; Haraguchi M; Tabata S; Furukawa T; Che XF; Zhang S; Oka T; Fukushima M; Nakagawa M; Ono M; Kuwano M; Akiyama S
Cancer Res; 2008 Sep; 68(17):7035-41. PubMed ID: 18757417
[TBL] [Abstract][Full Text] [Related]
28. A novel role of thrombospondin-1 in cervical carcinogenesis: inhibit stroma reaction by inhibiting activated fibroblasts from invading cancer.
Wu MP; Young MJ; Tzeng CC; Tzeng CR; Huang KF; Wu LW; Chou CY
Carcinogenesis; 2008 Jun; 29(6):1115-23. PubMed ID: 18413367
[TBL] [Abstract][Full Text] [Related]
29. Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis.
Albertsson P; Lennernäs B; Norrby K
Acta Oncol; 2009; 48(3):418-25. PubMed ID: 18932044
[TBL] [Abstract][Full Text] [Related]
30. Alterations of tumour cells, stroma and apoptosis in rat prostatic adenocarcinoma following treatment with histamine, interleukin-2 and irradiation.
Johansson S; Landström M; Henriksson R
Anticancer Res; 1999; 19(3A):1961-9. PubMed ID: 10470141
[TBL] [Abstract][Full Text] [Related]
31. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.
Stempak D; Gammon J; Halton J; Moghrabi A; Koren G; Baruchel S
J Pediatr Hematol Oncol; 2006 Nov; 28(11):720-8. PubMed ID: 17114958
[TBL] [Abstract][Full Text] [Related]
32. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
33. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
[TBL] [Abstract][Full Text] [Related]
34. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
[TBL] [Abstract][Full Text] [Related]
35. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
[TBL] [Abstract][Full Text] [Related]
36. [Potentiation of focal ultrasound treatment of prostate adenocarcinoma by concomitant chemotherapy with estramustine phosphate and paclitaxel].
Paparel P; Chapelon JY; Curiel L; Rabilloud M; Chesnais S; Gelet A
Prog Urol; 2004 Feb; 14(1):40-6. PubMed ID: 15098750
[TBL] [Abstract][Full Text] [Related]
37. Correlation between the expression of thrombospondin-1 and neovascularization in mucoepidermoid carcinoma.
Yang S; Wang XY; Guo LJ; Tang XF; Gao QH; Xuan M; Zhang Q; Tan K; Wen YM; Wang CM; Xu RA; Cao YT
Chin Med J (Engl); 2008 Oct; 121(19):1875-81. PubMed ID: 19080117
[TBL] [Abstract][Full Text] [Related]
38. Differential involvement of TGF-beta1 in mediating the motogenic effects of TSP-1 on endothelial cells, fibroblasts and oral tumour cells.
Motegi K; Harada K; Ohe G; Jones SJ; Ellis IR; Crouch DH; Schor SL; Schor AM
Exp Cell Res; 2008 Aug; 314(13):2323-33. PubMed ID: 18555217
[TBL] [Abstract][Full Text] [Related]
39. Thrombospondin 1 and its mimetic peptide ABT-510 decrease angiogenesis and inflammation in a murine model of inflammatory bowel disease.
Punekar S; Zak S; Kalter VG; Dobransky L; Punekar I; Lawler JW; Gutierrez LS
Pathobiology; 2008; 75(1):9-21. PubMed ID: 18334835
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
